Invasive infections: Table I ( 1-7) summarizes variations in incidence of invasive pneumococcal disease per 100,000 inhabitants by country and partially by year. Except for the low values in 1997 in Sweden (3) , the average rate is approximately 10/ 100,000 inhabitants. The average rate masks a significant increase in incidence in Denmark from 1992 (9). Table 2 (1,2,4,5 , 7-10) reveals the variation in the incidence of pneumococcal septicemia by age. The incidence is bimodal, with one peak before two or five years of age, depending on the series, and another in persons 65 years of age and older. with a gradual increase after age 65 years -for example, the incidence is 70/ 100,000 in adults older than 85 years in France (Figure l) . The Finnish data on children younger than age 16 show a growing increase in the incidence rate between 1983 and 1994 from 53/100,000 before age two years to 110/100,000 with no rational explanation (9) . Fedson et al ( 11 ), in a forthcoming article, report a significant increase in pneumococcal incidence rates in 1996 -47/100,000 in Sweden , 80/100 ,000 in Denmark and 62/100 ,000 in Norway (personal communication). This corresponds to published rates in North America. Despite comparable collection techniques, the same trend is not reported in France, where the rate has been stable since 1991 (Figure 2) . In Sweden, opinions are divided. Some believe that there is an actual increase (12) , while others believe the increase has been artificially created by a spontaneous increase in strains sent to the reference centres (13) , especially because penicillin-resistant strains are more common (7). Table 3 shows the incidence of pneumococcal meningitis by country. The incidence rates are even more similar between them from one country to another -around 1/ 100,000 cases per year (range 0.6/100 ,000 in England-Wales to 2.1/100,000 for Asians living in the North East Thames region of England [14] ). Children have an increased incidence of pneumococcal meningitis (8); children younger than six months of age have an incidence rate of 7.1/100,000, children younger than one year 6.8/100,000, children younger than two years 4. 7/100,000, children younger than five years 2.1/100,000, and children younger than 16 1/100,000 (the adult rate).
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Since the Haemophilus ir!fluenzae type b vaccine came into widespread use , pneumococcus has become the leading cause of purulent meningitis in France (Figure 3 ), as in other countries. In adults , the incidence increases beginning at age 65 years (5 , 7). As with septicemia , the sex ratio favours men in all European countries . Serotype distribution varies from one country to the next or from one year to the next, but 85% to 95% are contained in the 23-valent vaccine. In France, 85.6% of serotypes are contained in a heptavalent vaccine conjugate for meningitis (15) . Pneumonia: Pneumococcal pneumonia is considered the leading cause of community-acquired pneumonia (16) , even though the diagnosis may not be definitive. This contrasts with invasive infections, where the diagnosis is made after isolation of pneumococcus from a normally sterile site, mainly blood and cerebrospinal fluid. Incidence rates vary according to the diagnostic method used (eg, blood culture, protected bronchial sampling with or without brushing, bronchial aspiration, expectoration, indirect methods such as pneumolysin antibody testing or testing for antigens in urine, serum or expectoration). This leads to great variation in the results of epidemiological studies. The difficulty is heightened by the poor performance of diagnostic tests ; approximately 50% of pneumonias have a definite microbiological diagnosis. Incidence can be assessed by prospective studies (17, 18, 19) or from discharge codes (code 480 to 486, International Classification of Disease [of World Health Organization-9]) for patients hospitalized in institutions taking in the majority of patients for a Berg el al (35) Kragsbj erg el al (36) ---England (N orth Easl Thames Region)
Urw in el al (14) W ales and England Aszke nsay et al (7) Finland anklamp n cl al (4) given population (20.21 ) . Pneumococcal infections can be calculated on the basis of specific groups of patients to whom ratios found in the literature are applied (20, 21 ) . For example , at least 80% of pneumococcal-positive blood cultures are associated with pneumonia ; 5% to 30% (15% to 20% in general) of pneumococcal pneumonia is accompanied by a positive blood culture. Therefore, it is possible to determine the approximate number of cases of pneumococcal pneumonia hospitalized per year if the number of cases septicemia in that country correlated to the population is known. Table 4 (17-23) summarizes the rare studies of pneumonia incidence. There is a great variation in the data concerning pneumonia of all etiologies combined; in particular, the inciCan J Infect Di s Vol 10 Suppl A January/ February 1999 dence in England is low (the methodology in this study did not include chest x-rays) (1 7). The Finnish studies were based on clinical and radiological criteria (18, 19) . The French study was based in part on pneumonia diagnoses in hospital, which generally included an x-ray on admission (20) . In those patients older than 60 to 65 years of age, the incidence rate rises significantly.
The incidence of pneumonia increases with age ( Figure 4) , especially beginning at age 60 years, as found in Finland, Holland and France. In general, pneumonia-related mortality also varies according to age, as well as out-patient (3% on average) or in-patient (9% on average; more than 25% in bacteremicassociated cases) management. Pneumococcus is rarely spon- 
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comorbidity ( 19% compared with 4% [24] ) . In western Europe as a w hol e, Fedson et al (11) estimates the annual number of hospitalized cases of pneumonia of all etio logies combi ned to be 575,300 in subjects older than 65 years of age. Pneumococcus was found to be responsible for 172,590 to 287,650 cases. The annual number of deaths was found to be 76,500 (11) .
EPIDEMIOLOGY OF RESISTANCE
Antimicrobial-res istant Streptococcus pneumoniae is a genuine pandemic. Res istance varies widely from one coun try to another in Europe. It is very high in Spain (greater than 40%) and France (greater than 40% in 1996), and rare in northern Europe. Tab le 5 ( 15, (25) (26) (27) (28) (29) (30) (31) (32) summarizes the data on the differences, with surprisingly diametrically opposed rates for countries bordering each other such as Belgium and France. Antibiotic prescribing habits definitely play a major role, in particu la r the overconsumption of antibiotics in young children (over 60% of pneumococcal otitis cases in France are resistant to penicillin) . Resistance to macrolides varies from one cou ntry to another ; it was low in Spain when pneumococcus with reduced susceptibility to penicillin emerged (31) but was already higher in France (greater than 25%) (15) . The increase in resistance to macrolides in Belgium para llels an increase in the consumption of this family of antibiotics (27) . The low incidence in Italy is apparently due to the preference for intravenous administration of ceph alosporins (29) . The resistant strains consist mainly of serotypes 23, 6, 9 and 14 in most cou n tries. Epidemic strains, such as strain 23 , have been described in Spain , Iceland and the Un i ted States.
The very co mmon resistance in meningeal and ear, nose and throat infection s is becoming increasingly frequent in France, about 30% for septicemi a and pne umonia (15 ,33) . The (25) Sweden (26) Belgium (27) Holl and (28) Germany (3 0) Italy (29) Spain ( constant, gradual development of resistance in countries such as Spain and France, and Hungary and Poland (34) suggests that resistance will spread to neighbouring countries. CONCLUSIONS Invasive pneumococcal infections are a genuine public health problem in Europe because of their frequency and the development of multiple antibiotic resistance. Unfortunately, they are not notifiable diseases, and their epidemiology is not known in a uniform, accurate way. Rates of invasive infections are comparable in different countries; the average rate is 10/ 100,000 , of which approximately 1/100,000 are meningitis. The average figures hide disparities from one country to another, with an increase reported in the northern European countries, Denmark in particular. They also hide the bimodal distribution with a high rate before the age of two years , especially for meningitis, and an increasing rate in persons older than 65 years of age, in a quasilinear fashion . The data regarding pneumonia are more disparate, but all point to the prominence of pneumococcus, a large number of hospitalizations and a mortality rate (about 10%). The heaviest toll is in persons older than 60 years of age, particularly those over 80 years of age.
The epidemiology of resistance is distributed unevenly and is disturbing because of its rate. The high level of resistance in France or Spain leads to the fear that this situation is irreversible as histo1y has shown for the resistance of Staphylococcus aureus to penicillin. Just beginning in other countries, resistance must be surveyed regarding the risk of increase in the future. Awareness of this epidemiology definitely implies that a policy for antibiotic use, in particular in children, and a vaccination policy with perhaps, in the future, the eradication of the carriage of multiresistant strains through vaccination with a conjugate vaccine, could be a hope (37) . In the meantime, vaccine prevention must remain or become a major objective.
